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The BB2 receptor, belonging to the Bombesin receptor family, has been shown to be highly over 
expressed in a variety of cancer cell lines, including human prostate cancer. Over expression of 
the BB2 receptor offers an appealing target for the design of targeted radiopharmaceuticals.  
The Hoffman laboratory and others have been involved, for over a decade, in synthesizing 
Bombesin analogues that target the BB2 receptor for the purpose of developing a viable 
radiopharmaceutical for diagnostic or therapeutic treatment of cancer. Radiopharmaceuticals 
based on Bombesin analogues are typically composed of a targeting vector, radioisotope, 
chelator and linking group [See Bifunctional Conjugate Design figure below]. Previous studies 
have shown that variations in linking groups may affect the retention time of the bifunctional 
conjugate in prostate cancer (PC-3) cells.  Higher retention time allows for more efficacious 
therapeutic benefits and enhanced diagnostic imaging capabilities.  In the work presented, we 
designed and synthesized a 111In-Bombesin analogue with a phenyl linker group in order to 
determine if the phenyl linker group would provide higher retention times in prostate cancer.  In-
vitro analysis of the radiopharmaceutical was performed using PC-3 cells to determine the 
affinity of the new compound for the BB2 receptor to be 1.09 nM. In-vivo studies of the 
radiopharmaceutical were also conducted by injection of the radiopharmaceutical into CF-1 
(“normal”) mice, as well as SCID (Severe Combined Immunodeficient) mice bearing 2-3 week 
old PC-3 tumors. Experimental results on SCID mice revealed uptakes of 6.36, 3.34, 2.42 and 
1.69 % Injected Dose of radiopharmaceutical per gram of tumor tissue at 0.25, 1, 4 and 24 
hours, respectively. Imaging using Micro-SPECT (Single-Photon Emission Computed 
Tomography) was performed to track the dispersion of the radiopharmaceutical throughout the 
mouse model and confirmed the targeted uptake of the radiopharmaceutical. 
 
  
